110.40 USD
▲-0.90+4.13%
盘后 105.28 -0.70%
2026-08-03
市值
$6.04B
市盈率
—
EPS
-4.17
股息率
—
52 周区间
18.08 – 114.55
成交量
636.62K
Beta
0.08
目标价
129.75
52W 低 18.0852W 高 114.55
价格走势
公司简介
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...